Fibroblast growth factor 21 corrects obesity in mice.

By T. Coskun, Holly A. Bina, Michael A Schneider, J. Dunbar, Charlie C. Hu, Yanyun Chen, D. Moller, A. Kharitonenkov. Endocrinology, 2008

1,024 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/830e91615baf4e2f2276fb200e712d3021aa1cd9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State (2010, background): “FGF21 administration leads to weight loss in rodents, and its actions are considered anorexigenic (6).”
Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis Through Adipose Tissue Crosstalk (2016, background): “euglycemia, ameliorates hyperlipidemia, and decreases fat mass in animal models of obesity and T2DM (Coskun et al., 2008; Kharitonenkov and Larsen, 2011; Kharitonenkov et al., 2005).”
Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training (2013, neutral): “Muscle-derived factors including IL-6 (100, 101, 492, 493) IL-15 (514), BNDF (365, 424, 520), FGF21 (29, 64, 132, 164, 311, 349), and Follistatin-like 1 (482, 484), and SPARC (466) are a few putative myokines currently under investigation.”
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease (2010, background): “As a pharmacologic agent, administration of FGF21 to obese mice and diabetic monkeys leads to weight loss and marked improvement in glucose and lipid parameters (7, 18, 19).”
Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease (2020, background): “FGF21 has received a lot of attention for its insulin-sensitizing and weight loss-inducing effects when administered pharmacologically (139).”
Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. (2013, background): “C pies have been shown to counteract obesity and its related metabolic disorders in both rodents and nonhuman primates, including reduction of adiposity and alleviation of hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, and fatty liver disease (Xu et al., 2009b; Coskun et al., 200”
FGF/FGFR signaling in health and disease (2020, background): “FGF21 can cause weight loss, decrease plasma glucose and triglycerides level, and improve insulin sensitivity in obese and diabetic animal models without affecting total caloric intake.(553,554) Mice with overexpressed FGF21 resist to DIO.”
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. (2013, background): “Importantly, plasma LY levels were also within the range of efficacious exposures of LY (or human recombinant FGF21) achieved in animal models (Coskun et al., 2008; Kharitonenkov et al., 2005; Wente et al., 2006; Kharitonenkov et al., 2013).”